InnoPharmax (TPEX:4172) - Share price, News & Analysis

4172 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

4172 Stock Overview

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan.

Risk Analysis

Does not have meaningful revenue (NT$48M)

Does not have a meaningful market cap (NT$1B)

InnoPharmax Competitors

Price History & Performance

Summary of all time highs, changes and price drops for InnoPharmax
Historical stock prices
Current Share Price	NT$13.65
52 Week High	NT$20.80
52 Week Low	NT$11.90
Beta	1.31
1 Month Change	-17.02%
3 Month Change	-22.66%
1 Year Change	-18.75%
3 Year Change	53.37%
5 Year Change	-35.80%
Change since IPO	-62.08%

Recent News & Updates

Feb 22

Would Shareholders Who Purchased InnoPharmax's (GTSM:4172) Stock Five Years Be Happy With The Share price Today?

InnoPharmax Inc. ( GTSM:4172 ) shareholders should be happy to see the share price up 12% in the last month. But that...

Shareholder Returns

	4172	TW Pharmaceuticals	TW Market
7D	-5.5%	-4.6%	-3.4%
1Y	-18.8%	3.0%	0.7%

Return vs Industry: 4172 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 4172 underperformed the TW Market which returned 0.7% over the past year.

Price Volatility

Is 4172's price volatile compared to industry and market?
4172 volatility
4172 Average Weekly Movement	6.1%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.3%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 4172 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 4172's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2005	33	n/a	https://www.innopharmax.com

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company’s core products include N11005, a prandial oral insulin and GemOral. Its core technology is OralPAS Pro platform, a solid-SMEDDS dosage form composed of peptide drug, solvent, co-solvent, and surfactant adsorbed onto granules by inert excipients.

InnoPharmax Fundamentals Summary

How do InnoPharmax's earnings and revenue compare to its market cap?
4172 fundamental statistics
Market Cap	NT$1.18b
Earnings (TTM)	-NT$92.96m
Revenue (TTM)	NT$48.06m

24.6x

P/S Ratio

-12.7x

P/E Ratio

Is 4172 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
4172 income statement (TTM)
Revenue	NT$48.06m
Cost of Revenue	NT$40.65m
Gross Profit	NT$7.41m
Other Expenses	NT$100.38m
Earnings	-NT$92.96m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.07
Gross Margin	15.43%
Net Profit Margin	-193.44%
Debt/Equity Ratio	0%

How did 4172 perform over the long term?

See historical performance and comparison

Valuation

Is InnoPharmax undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

2.23x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4172's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4172's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 4172 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 4172 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4172's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 4172 is overvalued based on its PB Ratio (2.2x) compared to the TW Pharmaceuticals industry average (2x).

Future Growth

How is InnoPharmax forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

50.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InnoPharmax has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has InnoPharmax performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

5.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4172 is currently unprofitable.

Growing Profit Margin: 4172 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 4172 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.

Accelerating Growth: Unable to compare 4172's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4172 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).

Return on Equity

High ROE: 4172 has a negative Return on Equity (-17.49%), as it is currently unprofitable.

Financial Health

How is InnoPharmax's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 4172's short term assets (NT$209.3M) exceed its short term liabilities (NT$14.2M).

Long Term Liabilities: 4172's short term assets (NT$209.3M) exceed its long term liabilities (NT$10.4M).

Debt to Equity History and Analysis

Debt Level: 4172 is debt free.

Reducing Debt: 4172 had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4172 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4172 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 26.5% each year

Dividend

What is InnoPharmax current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4172's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4172's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4172's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4172's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 4172 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

InnoPharmax has no CEO, or we have no data on them.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/15 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31